Tagged with r&d

Canada Ronnie Miller, President & CEO of Roche Canada, shares the lessons learnt over his 17 years heading the affiliate, the interesting dynamics and developments within the Canadian healthcare space, Roche’s significant R&D footprint in Canada, and his focus on developing Roche Canada’s multiple sclerosis, hemophilia and neuroscience portfolios over the…

Canada Dr. Roman Szumski, vice-president of life sciences at the National Research Council (NRC), Canada’s industrial innovation and research organization, highlights the strategic and operational changes that have occurred over the past decade, NRC’s focus on promoting biologics and vaccines development within Canada’s life sciences environment, and NRC’s work in promoting…

Brazil Antonio Britto, the executive president of Interfarma, the main association gathering together local and international innovators in Brazil, provides insights into some of the hottest topics in Brazil’s pharmaceutical sector, including an assessment of the eye-catching growth prospects of the industry after years of political and economy turmoil, as well…

Tunisia Chokri Jeribi, country chair of Sanofi Tunisia since 2016, is responsible for the development and market leadership hold of Sanofi’s affiliate in Tunisia. In this interview he stresses the importance that clinical trials activities for both the company and the country. Additionally, Jeribi documents the unique collaboration system with local…

Austria Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern Europe, and the potential ramifications of the European Medicines Agency (EMA) relocating to the city. Could you please start by…

Bulgaria Ana Tsakova, managing director at Merck Bulgaria, emphasizes the duty of the industry to raise the bar of treatment quality in the country and shows the commitment of Merck in this regard to collaborate with both physicians and patients in key therapeutic areas such as oncology, fertility, multiple sclerosis, diabetes,…

Japan Makoto Suematsu, president of the Japan Agency for Medical Research and Development (AMED), discusses AMED’s successful unification of Japan’s previously disparate systems for medical research funding; the strategic significance of the country’s strong footprint in regenerative medicine and rare diseases; and the organization’s internationalization strategy, propelled by the push to…

Austria Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and the importance of open dialogue with specialists and patient groups. Furthermore, he highlights the need to differentiate health technology assessments…

Austria Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations. Furthermore, he points out the factors influencing the influx of innovative drugs into Austria, especially in rare diseases, and highlights…

Switzerland Giacomo Di Nepi, CEO of innovative Swiss specialty pharma outfit Polyphor, discusses his decision to join the company in 2016, his main priorities, and the potential impact of an IPO in the next two years. Having previously held senior leadership responsibilities with Takeda and Novartis, spending time as partner at…

Canada Andrew Casey, President and CEO of BIOTECanada, the national biotech association, provides an update on the Canadian biotech landscape, the strength of the Canadian R&D ecosystem, the growing investor community (both Canadian and foreign) looking to Canada as an untapped land of opportunities, and his hope to position Canada as…

Austria Maria Seriakov, CEO and founder of M bioserviceS, a young Austrian company dealing globally that specialises in logistics, regulatory affairs and quality control of biologics, discusses the challenges of navigating differing regulations across the globe as well as the how a hands-on approach ensures a product’s high quality. Furthermore, she…